Baseline characteristics in the ESPOIR cohort and outcome in ESPOIR and 1993 cohorts of patients who were followed up to 10 years
| . | ESPOIR cohort baseline n = 521 . | ESPOIR cohort 10 years n = 521 . | 1993 cohort 10 years n = 112 . |
|---|---|---|---|
| Variable | |||
| Age (years)° | 48.6 (11.6) 0° | 58.6 (11.6) 0° | 60.4 (12.5) |
| Female, n (%) | 408 (78.3) 0° | – | 90 (80.3) |
| Symptom duration* | 103.4 (50.1) 0° | – | – |
| Swollen joints (n) | 7.6 (5.3) 0° | 0.9 (2.1) (3.6)° | 3.3 (4.2) |
| Tender joints (n) | 8.5 (7.0) 0° | 2.1 (4.3) (3.8)° | 3.4 (4.5) |
| Patient global assessment (mm, VAS) | 59.7 (25.9) (0.4)° | 24.0 (24.0) (4)° | 26.2 (13.8) |
| Physician global assessment (mm, VAS) | 52.0 (22.2) 0° | 14.9 (18.1) (4.6)° | – |
| DAS28 ESR | 5.1 (1.3) (1.5)° | 2.5 (1.3) (11.6)° | – |
| DAS44 | – | – | 2.2 (0.9) |
| SDAI | 29.6 (14.5) (1.7)° | 7.5 (8.7) (6.9)° | – |
| CDAI | 27.4 (13.4) (0.4)° | 6.8 (8.3) (5.0)° | – |
| DAS28 ESR remission, n (%) | – | 273 (52.4) | – |
| CDAI remission | – | 207 (39.7) | – |
| DAS28 sustained remission, n (%) | – | 209 (40.1) | – |
| DAS28 drug-free remission, n (%) | – | 73 (14.1) | – |
| DAS28 ESR low disease activity | – | 336 (64.5) | – |
| HAQ-DI score | 1.0 (0.7) 0° | 0.5 (0.6) (1.3)° | 0.8 (0.7) |
| HAQ-DI < 0.5, n (%) | – | 280 (54.5) (1.3)° | – |
| SF36 MCS | 40.2 (11.1) (1.2)° | 46.7 (10.5) (1.9)° | – |
| SF36 PCS | 36.7 (8.5) (1.2)° | 44.6 (9.2) (1.9)° | – |
| Pain (mm, VAS) | 37.0 ( 27.9) (0.4)° | 16.6 (20.6) (4.4)° | 23.2 (23.0) |
| Fatigue (mm, VAS) | 47.3 (27.9) (0.4)° | 31.4 (27.0) (4.4)° | – |
| Rheumatoid nodules | 6 (1.2) (0.2)° | 39 (7.5) 0° | – |
| Sicca syndrome | 154 (29.7) (0.4)° | 314 (60.3) 0° | – |
| ESR (mm/h) | 29.4 (25.2) (0.9)° | 14.4 (14.0) (11.5)° | 18.4 (16.5) |
| CRP level (mg/l) | 20.2 (33.6) 0° | 6.4 (16.5) (4.6)° | 9.3 (11.7) |
| Normal CRP (<5 mg/l), n (%) | – | 336 (67.6) (4.6)° | – |
| Total mSharp score*** | 2.8 (5.0) (22.8)° | 13.7 (19.6) (23.6)° | 35.4 (46.1) |
| Erosion score | 0.8 (2.3) | 4.9 (9.4) | 18.4 (26.5) |
| Joint narrowing score | 2.1 (3.4) | 8.9 (12.1) | 32.1 (23.2) |
| Joint surgery | – | 82 (15.7) | 26 (23.2) |
| Joint arthroplasty/arthrodesis | – | 34 (6.5) | 20 (17.9) |
| ACPA (anti-CCP2) positivity, n (%) | 248 (47.6) 0° | – | 50 (57.9) |
| IgM-RF positivity, n (%) | 274 (52.6) 0° | – | 113 (59.1) |
| IgA-RF positivity, n (%) | 261 (50.1) 0° | – | 115 (60.2) |
| HLA shared epitope, n (%) | 291 (58.1) (3.8)° | – | 78 (70.2) |
| Current smoker, n (%) | 105 (20.2) 0° | – | – |
| Never smoker, n (%) | 277 (53.2) 0° | – | – |
| . | ESPOIR cohort baseline n = 521 . | ESPOIR cohort 10 years n = 521 . | 1993 cohort 10 years n = 112 . |
|---|---|---|---|
| Variable | |||
| Age (years)° | 48.6 (11.6) 0° | 58.6 (11.6) 0° | 60.4 (12.5) |
| Female, n (%) | 408 (78.3) 0° | – | 90 (80.3) |
| Symptom duration* | 103.4 (50.1) 0° | – | – |
| Swollen joints (n) | 7.6 (5.3) 0° | 0.9 (2.1) (3.6)° | 3.3 (4.2) |
| Tender joints (n) | 8.5 (7.0) 0° | 2.1 (4.3) (3.8)° | 3.4 (4.5) |
| Patient global assessment (mm, VAS) | 59.7 (25.9) (0.4)° | 24.0 (24.0) (4)° | 26.2 (13.8) |
| Physician global assessment (mm, VAS) | 52.0 (22.2) 0° | 14.9 (18.1) (4.6)° | – |
| DAS28 ESR | 5.1 (1.3) (1.5)° | 2.5 (1.3) (11.6)° | – |
| DAS44 | – | – | 2.2 (0.9) |
| SDAI | 29.6 (14.5) (1.7)° | 7.5 (8.7) (6.9)° | – |
| CDAI | 27.4 (13.4) (0.4)° | 6.8 (8.3) (5.0)° | – |
| DAS28 ESR remission, n (%) | – | 273 (52.4) | – |
| CDAI remission | – | 207 (39.7) | – |
| DAS28 sustained remission, n (%) | – | 209 (40.1) | – |
| DAS28 drug-free remission, n (%) | – | 73 (14.1) | – |
| DAS28 ESR low disease activity | – | 336 (64.5) | – |
| HAQ-DI score | 1.0 (0.7) 0° | 0.5 (0.6) (1.3)° | 0.8 (0.7) |
| HAQ-DI < 0.5, n (%) | – | 280 (54.5) (1.3)° | – |
| SF36 MCS | 40.2 (11.1) (1.2)° | 46.7 (10.5) (1.9)° | – |
| SF36 PCS | 36.7 (8.5) (1.2)° | 44.6 (9.2) (1.9)° | – |
| Pain (mm, VAS) | 37.0 ( 27.9) (0.4)° | 16.6 (20.6) (4.4)° | 23.2 (23.0) |
| Fatigue (mm, VAS) | 47.3 (27.9) (0.4)° | 31.4 (27.0) (4.4)° | – |
| Rheumatoid nodules | 6 (1.2) (0.2)° | 39 (7.5) 0° | – |
| Sicca syndrome | 154 (29.7) (0.4)° | 314 (60.3) 0° | – |
| ESR (mm/h) | 29.4 (25.2) (0.9)° | 14.4 (14.0) (11.5)° | 18.4 (16.5) |
| CRP level (mg/l) | 20.2 (33.6) 0° | 6.4 (16.5) (4.6)° | 9.3 (11.7) |
| Normal CRP (<5 mg/l), n (%) | – | 336 (67.6) (4.6)° | – |
| Total mSharp score*** | 2.8 (5.0) (22.8)° | 13.7 (19.6) (23.6)° | 35.4 (46.1) |
| Erosion score | 0.8 (2.3) | 4.9 (9.4) | 18.4 (26.5) |
| Joint narrowing score | 2.1 (3.4) | 8.9 (12.1) | 32.1 (23.2) |
| Joint surgery | – | 82 (15.7) | 26 (23.2) |
| Joint arthroplasty/arthrodesis | – | 34 (6.5) | 20 (17.9) |
| ACPA (anti-CCP2) positivity, n (%) | 248 (47.6) 0° | – | 50 (57.9) |
| IgM-RF positivity, n (%) | 274 (52.6) 0° | – | 113 (59.1) |
| IgA-RF positivity, n (%) | 261 (50.1) 0° | – | 115 (60.2) |
| HLA shared epitope, n (%) | 291 (58.1) (3.8)° | – | 78 (70.2) |
| Current smoker, n (%) | 105 (20.2) 0° | – | – |
| Never smoker, n (%) | 277 (53.2) 0° | – | – |
Data are mean (s.d.) unless indicated. °Rate of missing data.
Days between first swollen joints and ESPOIR screening.
At least at one yearly visit.
van der Heijde-modified total Sharp score.
°Median (range) 50.4 (17.4–72.7).
VAS: visual analogue scale; DAS28: disease activity score in 28 joints; HAQ-DI: Health Assessment Questionnaire Disability Index; SF36 MCS: Medial Outcomes Study 36-item Short Form mental component summary; SF36 PCS: Medical Outcomes Study 36-item Short Form physical component summary; ACPA: anti-citrullinated peptide antibodies; CCP2: cyclic citrullinated peptide; CDAI: Clinical Disease Activity Index; SDAI: Simple Disease Activity Index.
Baseline characteristics in the ESPOIR cohort and outcome in ESPOIR and 1993 cohorts of patients who were followed up to 10 years
| . | ESPOIR cohort baseline n = 521 . | ESPOIR cohort 10 years n = 521 . | 1993 cohort 10 years n = 112 . |
|---|---|---|---|
| Variable | |||
| Age (years)° | 48.6 (11.6) 0° | 58.6 (11.6) 0° | 60.4 (12.5) |
| Female, n (%) | 408 (78.3) 0° | – | 90 (80.3) |
| Symptom duration* | 103.4 (50.1) 0° | – | – |
| Swollen joints (n) | 7.6 (5.3) 0° | 0.9 (2.1) (3.6)° | 3.3 (4.2) |
| Tender joints (n) | 8.5 (7.0) 0° | 2.1 (4.3) (3.8)° | 3.4 (4.5) |
| Patient global assessment (mm, VAS) | 59.7 (25.9) (0.4)° | 24.0 (24.0) (4)° | 26.2 (13.8) |
| Physician global assessment (mm, VAS) | 52.0 (22.2) 0° | 14.9 (18.1) (4.6)° | – |
| DAS28 ESR | 5.1 (1.3) (1.5)° | 2.5 (1.3) (11.6)° | – |
| DAS44 | – | – | 2.2 (0.9) |
| SDAI | 29.6 (14.5) (1.7)° | 7.5 (8.7) (6.9)° | – |
| CDAI | 27.4 (13.4) (0.4)° | 6.8 (8.3) (5.0)° | – |
| DAS28 ESR remission, n (%) | – | 273 (52.4) | – |
| CDAI remission | – | 207 (39.7) | – |
| DAS28 sustained remission, n (%) | – | 209 (40.1) | – |
| DAS28 drug-free remission, n (%) | – | 73 (14.1) | – |
| DAS28 ESR low disease activity | – | 336 (64.5) | – |
| HAQ-DI score | 1.0 (0.7) 0° | 0.5 (0.6) (1.3)° | 0.8 (0.7) |
| HAQ-DI < 0.5, n (%) | – | 280 (54.5) (1.3)° | – |
| SF36 MCS | 40.2 (11.1) (1.2)° | 46.7 (10.5) (1.9)° | – |
| SF36 PCS | 36.7 (8.5) (1.2)° | 44.6 (9.2) (1.9)° | – |
| Pain (mm, VAS) | 37.0 ( 27.9) (0.4)° | 16.6 (20.6) (4.4)° | 23.2 (23.0) |
| Fatigue (mm, VAS) | 47.3 (27.9) (0.4)° | 31.4 (27.0) (4.4)° | – |
| Rheumatoid nodules | 6 (1.2) (0.2)° | 39 (7.5) 0° | – |
| Sicca syndrome | 154 (29.7) (0.4)° | 314 (60.3) 0° | – |
| ESR (mm/h) | 29.4 (25.2) (0.9)° | 14.4 (14.0) (11.5)° | 18.4 (16.5) |
| CRP level (mg/l) | 20.2 (33.6) 0° | 6.4 (16.5) (4.6)° | 9.3 (11.7) |
| Normal CRP (<5 mg/l), n (%) | – | 336 (67.6) (4.6)° | – |
| Total mSharp score*** | 2.8 (5.0) (22.8)° | 13.7 (19.6) (23.6)° | 35.4 (46.1) |
| Erosion score | 0.8 (2.3) | 4.9 (9.4) | 18.4 (26.5) |
| Joint narrowing score | 2.1 (3.4) | 8.9 (12.1) | 32.1 (23.2) |
| Joint surgery | – | 82 (15.7) | 26 (23.2) |
| Joint arthroplasty/arthrodesis | – | 34 (6.5) | 20 (17.9) |
| ACPA (anti-CCP2) positivity, n (%) | 248 (47.6) 0° | – | 50 (57.9) |
| IgM-RF positivity, n (%) | 274 (52.6) 0° | – | 113 (59.1) |
| IgA-RF positivity, n (%) | 261 (50.1) 0° | – | 115 (60.2) |
| HLA shared epitope, n (%) | 291 (58.1) (3.8)° | – | 78 (70.2) |
| Current smoker, n (%) | 105 (20.2) 0° | – | – |
| Never smoker, n (%) | 277 (53.2) 0° | – | – |
| . | ESPOIR cohort baseline n = 521 . | ESPOIR cohort 10 years n = 521 . | 1993 cohort 10 years n = 112 . |
|---|---|---|---|
| Variable | |||
| Age (years)° | 48.6 (11.6) 0° | 58.6 (11.6) 0° | 60.4 (12.5) |
| Female, n (%) | 408 (78.3) 0° | – | 90 (80.3) |
| Symptom duration* | 103.4 (50.1) 0° | – | – |
| Swollen joints (n) | 7.6 (5.3) 0° | 0.9 (2.1) (3.6)° | 3.3 (4.2) |
| Tender joints (n) | 8.5 (7.0) 0° | 2.1 (4.3) (3.8)° | 3.4 (4.5) |
| Patient global assessment (mm, VAS) | 59.7 (25.9) (0.4)° | 24.0 (24.0) (4)° | 26.2 (13.8) |
| Physician global assessment (mm, VAS) | 52.0 (22.2) 0° | 14.9 (18.1) (4.6)° | – |
| DAS28 ESR | 5.1 (1.3) (1.5)° | 2.5 (1.3) (11.6)° | – |
| DAS44 | – | – | 2.2 (0.9) |
| SDAI | 29.6 (14.5) (1.7)° | 7.5 (8.7) (6.9)° | – |
| CDAI | 27.4 (13.4) (0.4)° | 6.8 (8.3) (5.0)° | – |
| DAS28 ESR remission, n (%) | – | 273 (52.4) | – |
| CDAI remission | – | 207 (39.7) | – |
| DAS28 sustained remission, n (%) | – | 209 (40.1) | – |
| DAS28 drug-free remission, n (%) | – | 73 (14.1) | – |
| DAS28 ESR low disease activity | – | 336 (64.5) | – |
| HAQ-DI score | 1.0 (0.7) 0° | 0.5 (0.6) (1.3)° | 0.8 (0.7) |
| HAQ-DI < 0.5, n (%) | – | 280 (54.5) (1.3)° | – |
| SF36 MCS | 40.2 (11.1) (1.2)° | 46.7 (10.5) (1.9)° | – |
| SF36 PCS | 36.7 (8.5) (1.2)° | 44.6 (9.2) (1.9)° | – |
| Pain (mm, VAS) | 37.0 ( 27.9) (0.4)° | 16.6 (20.6) (4.4)° | 23.2 (23.0) |
| Fatigue (mm, VAS) | 47.3 (27.9) (0.4)° | 31.4 (27.0) (4.4)° | – |
| Rheumatoid nodules | 6 (1.2) (0.2)° | 39 (7.5) 0° | – |
| Sicca syndrome | 154 (29.7) (0.4)° | 314 (60.3) 0° | – |
| ESR (mm/h) | 29.4 (25.2) (0.9)° | 14.4 (14.0) (11.5)° | 18.4 (16.5) |
| CRP level (mg/l) | 20.2 (33.6) 0° | 6.4 (16.5) (4.6)° | 9.3 (11.7) |
| Normal CRP (<5 mg/l), n (%) | – | 336 (67.6) (4.6)° | – |
| Total mSharp score*** | 2.8 (5.0) (22.8)° | 13.7 (19.6) (23.6)° | 35.4 (46.1) |
| Erosion score | 0.8 (2.3) | 4.9 (9.4) | 18.4 (26.5) |
| Joint narrowing score | 2.1 (3.4) | 8.9 (12.1) | 32.1 (23.2) |
| Joint surgery | – | 82 (15.7) | 26 (23.2) |
| Joint arthroplasty/arthrodesis | – | 34 (6.5) | 20 (17.9) |
| ACPA (anti-CCP2) positivity, n (%) | 248 (47.6) 0° | – | 50 (57.9) |
| IgM-RF positivity, n (%) | 274 (52.6) 0° | – | 113 (59.1) |
| IgA-RF positivity, n (%) | 261 (50.1) 0° | – | 115 (60.2) |
| HLA shared epitope, n (%) | 291 (58.1) (3.8)° | – | 78 (70.2) |
| Current smoker, n (%) | 105 (20.2) 0° | – | – |
| Never smoker, n (%) | 277 (53.2) 0° | – | – |
Data are mean (s.d.) unless indicated. °Rate of missing data.
Days between first swollen joints and ESPOIR screening.
At least at one yearly visit.
van der Heijde-modified total Sharp score.
°Median (range) 50.4 (17.4–72.7).
VAS: visual analogue scale; DAS28: disease activity score in 28 joints; HAQ-DI: Health Assessment Questionnaire Disability Index; SF36 MCS: Medial Outcomes Study 36-item Short Form mental component summary; SF36 PCS: Medical Outcomes Study 36-item Short Form physical component summary; ACPA: anti-citrullinated peptide antibodies; CCP2: cyclic citrullinated peptide; CDAI: Clinical Disease Activity Index; SDAI: Simple Disease Activity Index.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
